Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Systematic dissection of transcriptional regulatory networks by genome-scale and single-cell CRISPR screens

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Immunosuppressive cells in the tumor microenvironment allow cancer cells to escape immune recognition and support cancer progression and dissemination. To improve therapeutic efficacy, we designed a liposomal oxaliplatin formulation (PCL8-U75) that elicits cytotoxic effects toward both cancer and immunosuppressive cells via protease-mediated, intratumoral liposome activation. The PCL8-U75 liposomes displayed superior therapeutic efficacy across all syngeneic cancer models in comparison to free-drug and liposomal controls. The PCL8-U75 depleted myeloid-derived suppressor cells and tumor-associated macrophages in the tumor microenvironment. The combination of improved cancer cell cytotoxicity and depletion of immunosuppressive populations of immune cells is attractive for combination with immune-activating therapy. Combining the PCL8-U75 liposomes with a TLR7 agonist induced immunological rejection of established tumors. This combination therapy increased intratumoral numbers of cancer antigen-specific cytotoxic T cells and Foxp3- T helper cells. These results are encouraging toward advancing liposomal drug delivery systems with anticancer and immune-modulating properties into clinical cancer therapy.

TidsskriftScience Advances
Udgave nummer36
Sider (fra-til)eaba5628
StatusUdgivet - sep. 2020

Bibliografisk note

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

ID: 62427965